Wallenstein Gene V, Blaisdell-Gross Bonnie, Gajria Kavita, Guo Amy, Hagan Michael, Kornstein Susan G, Yonkers Kimberly A
QualityMetric Incorporated, Lincoln, Rhode Island 02865, USA.
J Womens Health (Larchmt). 2008 Apr;17(3):439-50. doi: 10.1089/jwh.2007.0377.
To develop and validate the Premenstrual Symptoms Impact Survey (PMSIS), a brief web-based instrument for evaluating the impact of premenstrual symptoms on health-related quality of life (HRQOL).
An item bank of 68 questions was administered to a nationally representative sample of 971 women using the web, aged 18-45, who experienced regular menstrual cycles in the past 3 months, were not currently pregnant or breastfeeding, and were not being treated or taking medications for depression-related disorders in the last 2 years. Item reduction was performed using forward stepwise linear regression of an overall symptom severity score onto item scores. Three standards were used to validate the instrument: (1) the American College of Obstetricians and Gynecologists retrospective diagnostic criteria for identifying participants "at risk" for clinically significant premenstrual syndrome (PMS), (2) the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders retrospective diagnostic criteria for identifying participants at risk for premenstrual dysphoric disorder (PMDD), and (3) the Medical Outcomes Study Short Form (SF-12) Health Survey.
Six items met entry criteria in the model. Approximately 6.0% of the participants were identified as being at risk for PMDD, and 17.3% were identified as being at risk for clinically significant PMS. PMSIS scale score differed significantly between participants who were and were not at risk for PMDD/clinically significant PMS. PMSIS scale score also differed significantly between participants having either high, average, or low HRQOL as defined by SF-12 physical and mental component summary scores.
These results demonstrate that the PMSIS has excellent discriminative ability to detect differences in groups that are known to differ in terms of clinical criteria. The PMSIS can be used to educate consumers about the impact of their symptoms on QOL.
开发并验证经前症状影响调查问卷（PMSIS），这是一种基于网络的简短工具，用于评估经前症状对健康相关生活质量（HRQOL）的影响。
对971名年龄在18 - 45岁、过去3个月月经周期规律、目前未怀孕或哺乳、过去2年未接受抑郁症相关疾病治疗或未服用相关药物的女性进行全国代表性抽样，通过网络发放包含68个问题的题库。采用将总体症状严重程度评分对各项目评分进行向前逐步线性回归的方法进行项目缩减。使用三个标准对该工具进行验证：（1）美国妇产科医师学会用于识别具有临床显著经前综合征（PMS）“风险”参与者的回顾性诊断标准；（2）美国精神病学协会《精神疾病诊断与统计手册》用于识别经前烦躁障碍（PMDD）风险参与者的回顾性诊断标准；（3）医疗结果研究简表（SF - 12）健康调查。
模型中有6个项目符合纳入标准。约6.0%的参与者被确定为有患PMDD的风险，17.3%的参与者被确定为有患临床显著PMS的风险。有和没有PMDD/临床显著PMS风险的参与者之间，PMSIS量表得分差异显著。根据SF - 12身体和心理成分汇总得分定义为高、中、低HRQOL的参与者之间，PMSIS量表得分也存在显著差异。
这些结果表明，PMSIS具有出色的辨别能力，能够检测出已知在临床标准方面存在差异的群体之间的差异。PMSIS可用于让消费者了解其症状对生活质量的影响。
